Loading...
Market
What will be the next dermatological product acquisition by Organon by December 31, 2024?
2
Resolution / Starting Odds
Alopecia treatment • 25%
Psoriasis treatment • 25%
Eczema treatment • 25%
Other • 25%
Organon's press releases and financial news reports
Story
Organon Acquires Roivant's Dermavant for $1.2 Billion, Including VTAMA Cream
Sep 18, 2024, 11:36 AM
Organon has announced its acquisition of Dermavant, a subsidiary of Roivant Sciences ($ROIV), in a deal valued at $1.2 billion. The acquisition includes Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) Cream, 1%. The deal involves an upfront payment of $175 million, with additional payments up to $1.2 billion contingent on sales milestones and approval in atopic dermatitis. This acquisition underscores Organon's commitment to expanding its portfolio in dermatology.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by up to 10% • 25%
Decrease by up to 10% • 25%
Decrease by more than 10% • 25%
Less than $500 million • 25%
$500 million to $799 million • 25%
$800 million to $1 billion • 25%
More than $1 billion • 25%
Mostly Positive • 25%
Mostly Negative • 25%
Mixed • 25%
Neutral • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
GSK • 25%
Other • 25%
Strong Buy • 25%
Buy • 25%
Hold • 25%
Sell • 25%
Yes • 50%
No • 50%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%